Daiichi Life Insurance Co. Ltd. Takes $1.77 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Daiichi Life Insurance Co. Ltd. bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, HoldingsChannel.com reports. The fund bought 5,873 shares of the biopharmaceutical company’s stock, valued at approximately $1,768,000.

Several other large investors also recently bought and sold shares of the business. MV Capital Management Inc. bought a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $25,000. HM Payson & Co. bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $27,000. Golden State Wealth Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $29,000. Finally, Manchester Capital Management LLC raised its position in shares of Alnylam Pharmaceuticals by 600.0% during the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 72 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on ALNY shares. JPMorgan Chase & Co. dropped their price target on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. BMO Capital Markets initiated coverage on Alnylam Pharmaceuticals in a research report on Wednesday, August 19th. They set an “outperform” rating and a $318.00 price objective on the stock. HC Wainwright cut their target price on Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. Bank of America decreased their price target on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. Finally, Oppenheimer lowered their price target on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a research report on Friday, July 31st. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $386.62.

Insiders Place Their Bets

In other news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares in the company, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $236.22 on Monday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $197.81 and a 1 year high of $495.55. The firm has a 50-day simple moving average of $267.02 and a two-hundred day simple moving average of $297.02. The company has a market cap of $31.61 billion, a P/E ratio of 43.91 and a beta of 0.30. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same quarter in the prior year, the firm posted ($0.51) earnings per share. The company’s quarterly revenue was up 66.9% on a year-over-year basis. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.